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Abstract: One of the major obstacles that must be overcome in the design of effective 
lentiviral vaccines is the ability of lentiviruses to evolve in order to escape from 
neutralizing antibodies. The primary target for neutralizing antibodies is the highly variable 
viral envelope glycoprotein (Env), a glycoprotein that is essential for viral entry and 
comprises both variable and conserved regions. As a result of the complex trimeric nature 
of Env, there is steric hindrance of conserved epitopes required for receptor binding so that 
these are not accessible to antibodies. Instead, the humoral response is targeted towards 
decoy immunodominant epitopes on variable domains such as the third hypervariable loop 
(V3) of Env. For feline immunodeficiency virus (FIV), as well as the related human 
immunodeficiency virus-1 (HIV-1), little is known about the factors that lead to the 
development of broadly neutralizing antibodies. In cats infected with FIV and patients 
infected with HIV-1, only rarely are plasma samples found that contain antibodies capable 
of  neutralizing  isolates from other clades. In this review we examine the neutralizing 
response to FIV, comparing and contrasting with the response to HIV. We ask whether 
broadly neutralizing antibodies are induced by FIV infection and discuss the comparative 
value of studies of neutralizing antibodies in FIV infection for the development of more 
effective vaccine strategies against lentiviral infections in general, including HIV-1. 
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1. Introduction 
The lentiviral Env is essential for viral entry, facilitating the attachment of the virus to cells through 
high affinity interactions with its cellular receptor(s). Infection with the primate and feline lentiviruses 
requires sequential interactions with a primary receptor and a co-receptor to trigger the conformational 
change in Env that allows fusion of the viral envelope and cellular membrane to proceed. Whereas 
CD4 is the primary receptor for human immunodeficiency virus (HIV) and simian immunodeficiency 
virus (SIV) [1–3], CD134 (OX40) is the primary receptor for feline immunodeficiency virus (FIV) [4]. 
HIV can use a range of seven transmembrane domain G-protein-coupled receptors as co-receptors for 
entry, the major co-receptors used are CXCR4, CCR5 and (to a lesser extent) CCR3 [5–9]. In contrast, 
all strains of FIV tested to date use CXCR4 as a co-receptor [10–15] and CCR5 does not function as a 
co-receptor for FIV. Env exists on the virion as a complex trimeric structure comprising variable and 
conserved regions. While conserved epitopes that form the binding site for the primary receptor are 
accessible to the humoral immune response, the co-receptor binding site is largely hidden and is only 
exposed following a conformational change triggered by engagement of the primary receptor. 
Moreover, much of the Env is protected from the humoral response by extensive N-linked 
glycosylation and by immunodominant epitopes on variable loops such as the third hypervariable 
loop (V3). 
The neutralizing response to HIV has been studied extensively and is reviewed elsewhere [16,17]. It 
is thought that the majority of HIV neutralizing antibodies are strain-specific, targeting determinants 
that are unique to a particular viral variant and its genetic relatives.  Occasionally, neutralizing 
antibodies are induced that recognize diverse viral strains; viruses of distinct clades and geographic 
origins and it is these broadly neutralizing antibodies that are the goal for lentiviral vaccine 
development. 
2. Measuring Neutralizing Antibody 
2.1. Assays for HIV Neutralizing Antibodies 
In order to quantify the level of neutralizing antibody in a sample of biological fluid, the sample is 
mixed with a known quantity of virus or viral antigen. The antibodies within the sample are allowed to 
interact with the virus before adding the mixture to an indicator cell or system in which the ability of 
the virus to grow or mediate an effect may be quantified. Thus, early HIV neutralization assays mixed 
infectious virus with serially-diluted sera before plating onto susceptible cells  [18,19].  However, 
preparing titrated stocks of HIV and quantifying infection in susceptible cells proved experimentally 
demanding and thus techniques were developed in which the HIV Env was “pseudotyped” onto the 
surface of the rhabdovirus vesicular stomatitis virus (VSV). The benefits of this technique, developed 
initially for the study of human T-lymphotropic virus (HTLV) [20], were the ability to prepare high 
titer stocks of VSV (HIV) pseudotypes that, when plated onto HIV-susceptible indicator cells, gave a 
marked and measurable cytopathic effect or “plaque assay” that was mediated by replication of VSV in 
the target cell. Such assays yielded valuable insights into the neutralization of HIV by experimentally-
induced immune sera  and sera from HIV-infected patients. However, as our understanding of the 
process of viral entry and replication developed, it became apparent that the strains of virus that grew Viruses 2011, 3                         
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readily in the laboratory in established cell lines were often not representative of primary field strains 
of virus. For example, adaptation for growth in established cell lines selected for viral variants that 
utilized  CXCR4 efficiently and, in doing so, altered the sensitivity of the virus to neutralizing 
antibody. Thus, many researchers consider the “gold standard” neutralizing antibody test to be that 
based upon primary peripheral blood mononuclear cells (PBMC) as the target cell and uncloned 
primary clinical (field) isolates. In this assay system, PBMC stimulated with phytohemagglutinin 
(PHA) are cultured with IL-2 before infection in the presence or  absence of the test antibodies. 
Inhibition of viral infection is measured by the detection of either HIV p24 antigen or   
reverse-transcriptase (RT) activity in the culture fluids. The main limitation of this system is the 
inherent variability in susceptibility of PBMCs to infection, which affects the reproducibility of the 
assay system [21]. Similarly, antibodies targeting the RT enzyme itself may affect an RT assay-based 
read-out. An alternative assay, updating the pseudotype-based approach introduced by Weiss et al. in 
1985, utilizes pseudotyped viruses that are generated by co-transfection of an env- and rev-deleted 
HIV backbone, together with the env clone of interest; the resulting pseudotypes are used to infect a 
transformed cell line expressing the appropriate viral receptors, such as TZMbl, a genetically 
engineered HeLa cell clone that expresses CD4, CXCR4 and CCR5 and contains a Tat-responsive 
reporter gene encoding the firefly luciferase enzyme [22,23]. This pseudotype-based assay has proved 
to be robust and highly reproducible [24,25]. Other advantages of this system include its shorter assay 
length (2–3 days compared to 4–6 days for the PBMC-based system) and the lack of cell–cell 
transmission [21]. However, primary cell-based assays and pseudotype virus assays may each reveal 
distinct patterns of cross-neutralization [26]. A comparison of the neutralization of a panel of HIV-1 
strains by the monoclonal antibodies b12 and 4E10 revealed 84% concordance between the primary 
cell-based assay and the pseudotype virus assay  with  monoclonal antibody  b12 but only 52% 
concordance  between the two assays  with 4E10  [27].  Similarly, an analysis of primary isolate 
neutralization by pooled plasmas revealed significant, bi-directional discordance between the two 
assay systems  [28]. It is possible that the discordance between the two systems stems from the   
HeLa-derived TZMbl cells expressing supra-physiological levels of CXCR4 and CCR5 and promoting 
infection via an endocytic route. In comparison, mitogen-stimulated PBMCs express lower levels of 
CXCR4 and CCR5 and support infection via direct fusion of the viral envelope and plasma membrane. 
Thus, while the TZMbl-based assay offers a more robust and reproducible system, the relationship 
between the neutralizing titers and humoral immunity to infection remains unclear. 
2.2. Assays for FIV Neutralizing Antibodies 
Novel isolates of FIV are conventionally isolated in primary cultures of mitogen-stimulated feline 
PBMC  [29], cells which express both CD134 and CXCR4  [4,30].  However the growth and 
manipulation of IL2-dependent cultures of feline PBMC is a technically demanding process and thus 
the propagation of primary strains of FIV proved challenging. Some primary isolates contain viral 
variants that have the ability to replicate in the (CD134-negative) CrFK fibroblast line [29] as well as 
in PBMC. These viral variants are easy to propagate and form syncytia or “plagues” in the monolayer 
of infected cells. Early FIV neutralization assays took advantage of these CrFK-adapted viruses to 
develop a focus reduction assay in CrFK cells and demonstrated the presence of neutralizing antibody Viruses 2011, 3                         
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in cats that had been naturally or experimentally infected with FIV [31–33]. Moreover, assays with cat 
antibodies against homologous or heterologous strains indicated the existence of FIV neutralization 
subtypes [32]. However, process of adaptation of the viruses for growth in CrFK cells selected for 
variants that were able to infect cells independently of CD134, via a direct interaction with CXCR4. 
During this process, the viral Env protein acquired mutations in the V3 loop homologue that increased 
the net charge of the loop. These mutations modulated (enhanced) the sensitivity of the virus to 
neutralizing antibodies directed against V3. Therefore, while CrFK-based assays proved informative in 
regard to the antigenic-relatedness of viruses, their significance to in vivo neutralization and vaccine 
protection was limited. Accordingly, PBMC-based neutralization assays were developed, measuring 
RT activity in the culture fluids to monitor inhibition of infection  [34].  Given the variability of   
PBMC-based methods, we developed a viral pseudotype-based neutralization assay to detect anti-FIV 
neutralizing antibodies. A series of HIV (FIV) luciferase pseudotypes were prepared by co-transfecting 
HEK-293T cells with plasmids encoding: (i) an env-deleted HIV provirus incorporating a luciferase 
reporter gene, pNL-Luc-E-R+ (11); and (ii) an FIV env gene expressed from the vector VR1012. The 
resulting HIV (FIV) luciferase pseudotypes were incubated with serial dilutions of each plasma sample 
in order to permit neutralization of the pseudotype to proceed, prior to the addition of substrate cells 
and further incubation. Infection with the residual, non-neutralized pseudotype was then quantified by 
measuring luciferase activity and the percent neutralization was calculated with reference to control 
wells containing no plasma.  Plasmas  were  classified  as  strongly  neutralizing  (≥80%),  moderately 
neutralizing (60–79%), and weakly neutralizing (40–59%) [35]. 
2.3. Optimization of the CLL-CD134-Based Assay for FIV Neutralizing Antibody 
FIV infects cells by sequential interactions with the primary receptor CD134 [4] followed by a 
second interaction with the chemokine CXCR4 [12,13]. Thus, target cells for FIV neutralization assays 
should express both CD134 and CXCR4. As CD134 expression in the cat is restricted predominantly 
to activated CD4+ helper T cells, there are relatively few cell lines that may serve as suitable substrates 
for FIV neutralizing  antibody assays. The MYA-1 cell line, an IL-2 dependent CD4+ feline 
lymphoblastoid cell line [36] expresses both CD134 and CXCR4 and has been utilized previously in 
FIV neutralization assays [37]. However, CXCR4 expression on MYA-1 cells is low (approximately 
10%), growth is slow, they are sensitive to manipulation and they are IL-2-dependent; all of which 
conspire to limit the utility of this cell line for routine neutralization assays. As an alternative, and to 
overcome these limitations, the cell line CLL-CD134, derived from a canine chronic lymphocytic 
leukemia and transduced with feline CD134 was developed  [38].  High expression of CD134 
(over 99%) was maintained over 40 passages of the CLL-CD134 cell line; the cells are IL-2 
independent, easily manipulated and robust with a high growth rate compared to MYA-1. When the 
susceptibility of MYA-1 and CLL-CD134 to infection with HIV (FIV) pseudotypes bearing diverse 
FIV Envs are compared, CLL-CD134 display a similar pattern of susceptibility to infection to MYA-1 
cells, but achieve significantly higher counts per minute compared with MYA-1 cells, indicating that 
CLL-CD134 offered an ideal replacement to MYA-1 cells as the substrate for subsequent FIV 
neutralizing antibody assays. Viruses 2011, 3                         
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3. FIV Neutralizing Antibodies 
3.1. Time Course of Neutralizing Antibody Production in FIV Infection 
Anti-FIV antibodies can be detected as early as 6 weeks post infection in experimentally infected 
cats [39]. Similarly, seroconversion can typically be detected between 2 and 4 weeks post infection 
with HIV  [40,41].  However, it takes longer for an anti-HIV-1 neutralizing antibody response to 
develop and not all infections induce a neutralizing response. Richman et al.  [42]  compared the 
neutralizing  response of three treatment-naive HIV-1 infected individuals to autologous virus and 
found marked differences in both response time and titer. Neutralizing antibodies capable of 
neutralizing the homologous virus may develop in the first months of infection [42–44], while cross 
reactive neutralizing antibodies develop over time in up to 30% of patients [45–48]. Non-neutralizing 
antibodies against Env may be detected as early as 2 weeks post infection for FIV [49]; however, little 
is known about the development of neutralizing antibodies in FIV-infected cats. In order to estimate 
the time required for the development of an anti-FIV neutralizing response in an infected cat, 
sequential samples collected from three cats infected experimentally with the GL8 molecular clone of 
FIV were examined for ability to neutralize HIV(FIV) pseudotypes bearing the homologous GL8 Env 
(Figure 1).  The results demonstrate that the  neutralizing antibody response to infection develops 
slowly over time, indeed within the first two years, only weak neutralization was detected (<50% 
neutralization at a plasma dilution of 1:10). By the end of the study period at approximately four years 
post-infection, virus neutralization in cats 611 (Figure 1A,B) and 612 (Figure 1C,D) had reached a 
plateau of 50 to 60%. The humoral response of cat 613 to infection appeared similar to those of 611 
and 612 initially, neutralization barely exceeding 40% in the first year. However, by approximately 
two years (99 weeks), post-infection a sharp increase in neutralizing activity was detected; a potent 
neutralizing response had been elicited that could reduce luciferase activity >1000-fold. During this 
period, the proviral load in the three cats remained remarkably stable [50], suggesting that the potent 
neutralizing response elicited in cat 613 was variant-specific, and did not ultimately influence the 
proviral burden of the animal. The primary focus for the response was the V5 loop of gp120 and was 
accompanied by the emergence of neutralization-resistant variants bearing V5 loop mutations 
(see below and [51,52]).  While it is possible that the GL8 strain of FIV may induce neutralizing 
antibodies very poorly, these preliminary data demonstrate that the neutralizing response to FIV can be 
both slow to develop and ultimately very weak. Further, given the stark difference between the 
responses of cats 611 and 612 and that of cat 613, they emphasize that inter-cat variation may be 
substantial. We have found previously that distinct combinations of viral variants evolved in each of 
the infected animals (611, 612 and 613) with time post-infection [51]. Accordingly, the nature of the 
neutralizing antibody response induced in each of the infected cats may have been shaped by both the 
composition of the viral quasispecies that evolved within the cat (the immunogen) and the ability of 
the cat to generate a humoral immune response to the virus (the immunogenetics of the host). Viruses 2011, 3                         
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Figure 1.  Longitudinal development of virus neutralizing antibodies in feline 
immunodeficiency virus (FIV)-infected cats.  Sequential plasma samples collected from 
three  cats (A,B—611,  C,D—612,  E,F—613) infected experimentally with a molecular 
clone of FIV GL8 were diluted 1:10 and examined for ability to neutralize HIV (FIV) 
pseudotypes bearing the GL8 Env as described [35]. Luciferase activity (A,C,E) was 
measured at three days post-infection and the percentage neutralization (B,D,F) calculated 
relative to a “no plasma” control. Each point is derived from the mean (n = 3) +/− SEM. 
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3.2. Prevalence of Neutralizing Antibodies in FIV Infected Cats 
Plasma samples were collected from 345 FIV sero-positive, naturally infected,  cats across the 
United Kingdom and submitted to the Companion Animal Diagnostic Service at the University of 
Glasgow. The cats ranged from 5 months to 18 years of age, although the ages of many of the animals Viruses 2011, 3                         
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were either unknown or estimated by the cats’ veterinarians. The study population also included   
FIV-infected cats held in cat protection shelters, strays awaiting adoption, or free-roaming cats. Cats 
within these groups are at greater risk of FIV infection, according to epidemiological studies [53]. The 
FIV-infected cats in this study were five times more likely to be male than female, consistent with 
previous studies which demonstrated that males are at a higher risk of FIV infection due to their more 
aggressive nature  [54]. Approximately one third of the cats displayed no clinical signs and were 
apparently healthy. However, not all cats had been examined thoroughly by veterinarians and so this 
proportion may have been overestimated. Clinical signs recorded for the sick cats included weight loss, 
dullness, anorexia, vomiting, inappetence, malaise, lethargy, pyrexia, anemia, jaundice, 
keratitis/uveitis, upper respiratory tract  signs, stomatitis/gingivitis, neurological signs and enlarged 
lymph nodes. Samples were screened for neutralizing antibodies using HIV (FIV) pseudotypes bearing 
the GL8 Env as a representative subtype A UK-derived strain of FIV. Since the plasma samples were 
collected from clinical cases, the time post-FIV infection was not known. However, comparison of the 
GL8 neutralizing activity revealed a full spectrum of activities, from no neutralization to 100% 
neutralization. It has been suggested that the neutralizing response may broaden with time   
post-infection, indeed, our own data from cats 611, 612 and 613 (Figure 1) suggest a slow, but 
significant, increase in the response with time post-infection. Therefore, since older FIV-positive cats 
may have been infected for longer, we examined the data collected from a subgroup of 214 cats for 
which age had been recorded, to determine whether older cats had higher levels of neutralizing 
antibodies (Figure 2). No relationship was evident between age and cross-neutralization of the GL8 
pseudotype. It was also notable that many samples contained either weak or no neutralizing antibody 
activity, and occasionally antibodies were detected that appeared to enhance infection (Figure 2).  
Figure 2. Relationship between estimated age and ability to neutralize FIV. 214 plasma 
samples from cats testing positive for FIV in the United Kingdom were diluted 1:10 and 
tested for ability to neutralize GL8 Env-bearing pseudotypes. Graph represents estimated 
age versus percentage neutralization relative to a no plasma control.  
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3.3. Broadly Neutralizing Antibodies 
The neutralizing antibody response to HIV develops over time and there is considerable variation 
between patients in both the potency of the response and the time it takes to develop  [42]. For 
example, Richman et al. found that while one patient achieved a neutralizing titer >1000 by 6 months 
post-infection, a second patient had no significant neutralizing antibody by 11 months post-infection [42]. 
The neutralizing response against homologous virus develops more slowly than the humoral response 
to Env per se, a pseudovirion-based assay detecting significant neutralizing antibodies by 30 weeks 
post-infection while anti-V3 peptide reactivity was evident as early as 10 weeks post-infection [44]. 
Comparisons of neutralizing activity in sera from HIV-1 infected individuals have indicated that the 
breadth of the neutralizing response varies between individuals. In many cases activity is narrow and 
strain-specific while sera from others may display broad intra-clade, and more rarely inter-clade, 
neutralizing antibody [45,47,55,56]. The sera that neutralize diverse HIV-1 isolates are deemed to 
contain broadly neutralizing antibodies and the induction of such broadly neutralizing antibodies is the 
ultimate goal of HIV vaccine design. Previous studies have suggested that true broadly neutralizing 
antibody are relatively rare and that much of the broad neutralizing activity within such sera is directed 
against gp120, targeting the CD4 binding site  [57],  although other specificities are thought to 
contribute [57,58]. The concept of broadly neutralizing antibodies has been extended further with the 
identification of “elite neutralizers”, a population of HIV-infected individuals (representing 1% of the 
1,234 individuals screened) possessing serum antibodies capable of neutralizing more than one strain 
of virus within a clade and across at least four clades [47].  
Little is known about the breadth of neutralizing activity within sera from FIV-infected cats. 
Therefore, we conducted a pilot survey of neutralizing activity in cats naturally infected with FIV, 
screening 345 plasma samples for neutralizing antibodies against the GL8  isolate. The samples 
containing neutralizing antibody were collected from cats aged between 18 months and 14 years. 
Subsequently, samples which strongly neutralized GL8 were tested against other isolates to assess the 
breadth of cross-reactivity. Of the 345 plasma samples that were tested, 30 (8.7%) strongly (i.e., ≥80% 
at a 1:10 dilution) neutralized GL8 Env-bearing pseudotypes. As isolates within the UK are almost 
exclusively subtype A [59], the absence of anti-GL8 neutralizing antibodies in the majority of the 
samples may suggest that the majority of infections either elicit strain-specific responses or do not 
elicit strong neutralizing antibody responses. Alternatively, the GL8 isolate may represent a strain of 
FIV that is largely resistant to neutralization. The 30 plasma samples containing neutralizing 
antibodies that strongly neutralized GL8 were tested next for the ability to neutralize HIV(FIV) 
pseudotypes bearing Envs from the U.S.A. subtype A strain PPR and USA subtype C strain CPG-41.  
6 samples were identified that neutralized GL8, PPR and CPG41 strongly; these samples were 
screened further against pseudotypes bearing Envs from a panel of 19 primary isolates, revealing two 
sera with broad cross-neutralizing activity, 206394 and  178639 (Table 1). Thus from an initial 
screening of 345 samples, only samples two exhibited broad, inter-subtype neutralizing activity, 
representing 10% of the plasma samples containing detectable neutralizing antibodies or 0.9% of all 
the samples tested from cats naturally infected with FIV. This proportion is similar to recent reports for 
HIV infections; plasma from 7 of 191 viremic patients (3.7%) and 3 of 174 aviremic patients receiving 
antiretrovirals (1.7%) contained broadly reactive neutralizing antibody [60]. Viruses 2011, 3                         
 
 
1878 
Table 1. Broad neutralization of FIV by plasmas from two FIV-infected cats. Percentage 
neutralization of HIV  (FIV) pseudotypes at a plasma dilution of 1:10 was calculated 
relative to a “no plasma” control sample. 
      Plasma 
Virus  Origin  Subtype  178639  206394 
GL8  UK  A  99  95 
180638  UK  A  99  90 
171838  UK  A  99  99 
180260  UK  A  96  96 
180140  UK  A  90  97 
178721  UK  A  99  97 
179200  UK  A  83  97 
206394  UK  A  83  93 
0425  UK  A  99  96 
0827  UK  A  99  95 
1419  UK  A  95  96 
PPR  USA  A  98  99 
B2542  USA  B  99  99 
KNG2  Japan  B  96  99 
TM2  Japan  B  99  99 
Pisa M2  Italy  B  93  100 
Leviano  Brasil  B  90  100 
CPG41  USA  C  96  99 
Poose  Sri Lanka  -  73  100 
LLV-B  Tanzania  -  51  16 
3.4. Determinants of FIV Neutralization 
The nature of the assay systems used to assess FIV neutralization in vitro indicated initially that the 
V3 loop was a major determinant for virus neutralization [32,33]. Subsequent studies revealed that the 
significance of antibodies targeting this region to the neutralizing response had been over-emphasized 
by the cellular substrate used to quantify neutralization. Formerly, assays were based on inhibiting 
infection of CrFK cells with “CrFK-adapted” strains of virus. The challenge viruses used in these 
assays were selected for growth in CrFK cells and, during this process of CrFK-adaptation, viruses 
were adapted to CD134-independent infection mediated by a direct interaction with CXCR4 
(analogous to CD4-independent infection with HIV). As the V3 loop plays a critical role in the FIV 
Env-CXCR4 interaction, CrFK-based assays exaggerated the importance of neutralizing antibodies 
binding this region  [61]. Accordingly, vaccines targeting selectively the FIV V3 loop proved 
ineffective at preventing infection [62]. A possible role for V3 in virus neutralization post-engagement 
of the viral receptor has been suggested [63] although neutralizing activity would only appear to be 
evident in assays performed in vitro in the presence of soluble forms of the viral receptor, CD134.  
Assays employing IL2-dependent T cells have suggested that there is little correlation between the 
efficiency of virus neutralization and the response to V3. In contrast, several studies have indicated 
important roles for the V4 and V5 regions in virus neutralization [64–67]. A possible linear epitope in Viruses 2011, 3                         
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the V5 region of the 19K1 strain was investigated using synthetic peptides [68]. A single mutation at 
position 560 in V5 may be involved concurrently with an additional mutation at 483 in the V4 loop to 
form a conformation-dependent determinant for neutralizing antibody  [68]. Independently, two 
mutations that resulted in the creation of potential sites for N-linked glycosylation in V4 (K481N) and 
V5 (S557N) contributed to the conversion of FIV from a neutralization-sensitive to neutralization-
resistant phenotype [65,69]. Further evidence for the importance of the V5 region of FIV to the control 
of viral replication in vivo has been uncovered in analyses of the evolution of a molecular clone of the 
GL8 strain over time. Five years post-infection of cats with an infectious molecular clone of FIV, viral 
variants were isolated from PBMC, their nucleic acid sequences determined  and their biological 
properties investigated. Variants had acquired mutations in the V5 loop that mediated escape from 
homologous neutralizing antibody [52]. 
By exchanging V5 loops between neutralization-resistant and neutralization-sensitive variants, the 
specificity of the neutralizing response was confirmed as targeting V5. The mechanism of escape from 
neutralization differed between variants, involving either shortening, lengthening or mutating of V5 
(Figure 3). The importance of V5 in FIV neutralization is not restricted to subtype A viruses; in a 
separate study a neutralization-resistant Japanese subtype B strain of FIV (NG4) escaped neutralization 
by homologous and heterologous sera following the elimination of a potential site for N-linked 
glycosylation in V5 [35]. The V5 loop of FIV Env is highly variable among isolates, with variation 
occurring not only within the amino acid sequence but also in the length of the central region (up to 
14 residues) towards the end of the loop structure formed by disulfide bond linkage. Length 
polymorphisms in this region of the FIV Env protein are  attributable largely to the reiteration of 
codons encoding serine and threonine residues, residues that possess hydroxyl side chains and may, 
potentially, undergo O-linked glycosylation. It is generally believed that O-linked oligosaccharides 
have only minor effects on the formation of the glycan shield on HIV Env compared to N-linked 
oligosaccharides (due to their small molecular size compared with N-linked glycans). However, as 
O-linked oligosaccharides have diverse structures with no common carbohydrate core, it is difficult to 
predict how efficient they may be in shielding neutralization epitopes, especially in regions where 
there are multiple adjacent sites for O-linked glycosylation [70]. X-ray crystallographic studies on 
HIV-1 gp120 have demonstrated that glycosylation may affect significantly the conformational 
stability of Env as well as having indirect effects on more distant sequences along the secondary 
structure. This in turn would affect the accessibility of epitopes for interactions with neutralizing 
antibody  [71]. Like FIV, HIV-1 evades the Env-targeted humoral immune response by the 
incorporation of amino acid substitutions, length polymorphisms (insertions and deletions) and by 
altering the pattern of glycosylation [42,72–76]. Recent data have indicated that population-level 
adaptation of HIV-1 gp120 to humoral immunity over time has been associated with an enhanced 
resistance of the virus to neutralizing antibody and that this resistance has coincided with both an 
increase in length of the variable loops and an increase in the number of potential sites for N-linked 
glycosylation [77]. It is striking that both the FIV and HIV Envs should incorporate similar changes in 
response to the host immune response and indicates that similar mechanisms are at play in 
FIV-infected cats as have been observed in HIV-infected individuals. By comparing and contrasting 
the two infections, valuable insights may be obtained into immunity to lentiviral infection and the 
prospects for the development of Env-based vaccines. Viruses 2011, 3                         
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Figure 3. Amino acid sequence variation in the V5 loop of viral variants isolated from a 
GL8-infected cat. Five years post-infection with a molecular clone of GL8, variants were 
isolated that were either sensitive (+) or resistant (−) to virus neutralizing antibody. 
Variants that were sensitive to homologous VNA had identical V5 sequences. (Adapted 
from [52]). 
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Escape from neutralizing antibody is facilitated by the acquisition of non-synonymous mutations 
over time and thus the rate of viral evolution in the infected animal will influence the ability of the 
virus to overcome a neutralizing response. Studies examining viral sequence variation over time in FIV 
infected cats  have concluded that in comparison with other lentiviruses, FIV is remarkably stable 
genetically [51,78–80], similar to observations with bovine immunodeficiency virus (BIV) infection of 
cattle [81]. It possible that the low rates of FIV evolution reported to date reflect slower replication 
kinetics of FIV. Previous studies have demonstrated that the degree of SIV divergence following 
infection of macaques was closely linked to the rate of viral replication. Thus, a virus which replicated 
more slowly diverged from the ancestral strain by 0.6% after 75 weeks while a rapidly replicating 
strain diverged by 1.4% after 75 weeks [82]. If FIV has a reduced replication rate, this may impact 
upon the frequency at which mutations facilitating escape from neutralization arise in infected cats. 
3.5. Neutralizing Antibodies Targeting the Membrane-Proximal External Region of FIV 
Among the broadly neutralizing antibodies that have been identified as targeting HIV-1,  three 
monoclonal antibodies (2F5, 4E10 and Z13) were found to recognize determinants on the viral 
transmembrane protein gp41. The antibodies bind to a highly conserved stretch of the transmembrane 
region of gp41 that lies immediately adjacent to the external surface of the viral lipid envelope, a 
region  referred to as the  membrane-proximal external region  (MPER) (reviewed comprehensively 
in [83]). An analogous region has since been identified in gp41 of FIV and peptides derived from this 
region are potent inhibitors of viral entry [84,85]. When a synthetic peptide derived from the FIV 
MPER (peptide 59) was coupled to Qβ virus-like particles and used to elicit anti-MPER antibodies in 
cats, potent anti-peptide responses were detected by enzyme-linked immunosorbent assay 
(ELISA) [85]. However, when the sera were screened for binding to the MPER, in the context of 
whole FIV virions, neither virus binding nor virus neutralization were detected [85]. The failure of 
peptide 59 to induce neutralizing antibodies may have been due to the peptide not being presented in 
the correct context; the MPER of HIV-1 is in close apposition with the viral envelope and thus may Viruses 2011, 3                         
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only adopt the conformation associated with the induction of neutralizing antibodies when in 
association with a lipid membrane. In an attempt to mimic the context in which the FIV MPER is 
presented on intact virions, cats were immunized with a lipoylated analogue of peptide 59 (lipo-P59 [86]). 
Immunization with lipo-P59 induced antibodies that were detectable by ELISA and which bound to 
FIV virions, in contrast to previous findings with the non-lipoylated form of the same peptide [87]. 
However, in comparison with sera from FIV-infected cats, the sera from lipo-P59-immunized cats 
contained no neutralizing antibodies [87], suggesting that although the lipoylation of the peptide had 
altered its conformation and immunogenicity, it did not offer a viable approach to the development of 
an  FIV vaccine.  Intriguingly, using a T cell based neutralization assay based on MBM  cells 
(an IL2-dependent cell line similar to MYA-1 cells [88]), the sera from the immunized cats were found 
to enhance FIV infection, an effect that could be adsorbed by pre-incubation with lipo-P59 [87]. While 
disappointing from a vaccine design perspective, these findings may prove informative in interpreting 
why some FIV vaccines that  failed to induce protective immunity, appeared to enhance infection 
following challenge [62,69,89–93]. 
3.6. Induction of FIV Neutralizing Antibodies by Vaccination 
Protection against FIV infection was first demonstrated by Yamamoto and colleagues using whole 
inactivated virus and cells prepared from the FL4 cell line, an IL-2 independent cell line persistently 
infected with the subtype A Petaluma strain of FIV (PET) [94,95]. However, immunity induced by the 
FL4-based vaccine did not extend to heterologous subtype A strain GL8  [96]. Further, protection 
afforded by the FL4 vaccine did not correlate with the potency of the neutralizing antibody response 
when assessed on a CrFK-based (V3-biased) assay and could not be replicated using affinity-purified 
Env [97]. It was noted that there were qualitative and quantitative differences in the nature of the 
immune response induced by the FL4-based vaccine and an affinity-purified Env-based vaccine [97]. 
Moreover, the FL4-based vaccine induced both antibodies that reacted with host cell proteins [97] and 
FIV-specific cytotoxic T cells [98,99], suggesting that additional factors may have contributed to 
immunity, a finding underlined by the observation that DNA vaccines could induce protection from 
FIV PET infection in the absence of a detectable humoral immune response  [39].  While passive 
transfer experiments indicated that humoral immunity could be transferred to kittens from  cats,  
the transfer experiments were followed by challenge with the neutralization-sensitive FIV PET strain 
of FIV [100].  
Why do FL4-based vaccines fail to protect against heterologous strains of virus? One possibility is 
that the prototypic vaccines failed to induce neutralizing antibody against conformational epitopes that 
would be required to confer heterologous immunity; evidence to date would suggest that the 
majority of the neutralizing responses that develop in vivo are strain-specific and target V4 and V5  
[35,52,65–69,101] while broadly neutralizing antibodies are rare. The breadth of the immunity induced 
by FL4-based vaccines has been extended by the introduction of heterologous strains of virus into the 
FL4 cell line  [102–104], and such vaccines have afforded limited success. However, whether the 
heterologous immunity induced by such vaccines reflects a qualitative or quantitative improvement in 
the neutralizing antibody response remains to be established. Broad-spectrum protection has yet to be 
achieved. It is possible that some strains of FIV are inherently more resistant to neutralizing antibody Viruses 2011, 3                         
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and that, as FIV has become adapted to its feline host, the virus has enhanced its ability to evade 
humoral immunity by shrouding itself in N-linked glycans extending its variable loops, similar to the 
mechanism that has been postulated for HIV-1  [77]. If this is the case, then it is possible that 
retargeting the immune response by selective deglycosylation of immunogens may reveal novel cryptic 
epitopes that may induce neutralizing antibodies and offer hope for the development of more highly 
efficacious FIV vaccines. 
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